Abstract
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited. In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 632 |
| Number of pages | 1 |
| Journal | Indian Journal of Dermatology |
| Volume | 59 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 1 2014 |
Fingerprint
Keywords
- Angiogenesis
- bevacizumab
- psoriatic arthritis
ASJC Scopus subject areas
- Dermatology
Cite this
Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer. / Datta-Mitra, Ananaya; Riar, Navdeep K.; Raychaudhuri, Siba P.
In: Indian Journal of Dermatology, Vol. 59, No. 6, 01.11.2014, p. 632.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer
AU - Datta-Mitra, Ananaya
AU - Riar, Navdeep K.
AU - Raychaudhuri, Siba P
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited. In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.
AB - Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited. In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.
KW - Angiogenesis
KW - bevacizumab
KW - psoriatic arthritis
UR - http://www.scopus.com/inward/record.url?scp=84908476374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908476374&partnerID=8YFLogxK
U2 - 10.4103/0019-5154.143574
DO - 10.4103/0019-5154.143574
M3 - Article
VL - 59
SP - 632
JO - Indian Journal of Dermatology
JF - Indian Journal of Dermatology
SN - 0019-5154
IS - 6
ER -